Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Doxorubicin; Ifosfamide
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
Most Recent Events
- 19 Aug 2021 Biomarkers information updated
- 03 Aug 2012 Planned end date changed from 1 Mar 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 22 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.